Oral gout medications are not effective at ridding patients of established tophi

In the U.S., individuals with severe gout have up to a 33-fold increase in comorbidities5

Individuals with tophi have up to a 3-fold increase in mortality risk compared to patients with gout 6

What is Chronic Severe Gout?

A subpopulation of gout patients suffers from chronic severe gout, which is typically characterized by a high burden of tophi (inflammatory nodules of crystalized uric acid) that donot respond to existing medications.

Patients with chronic severegout experience recurrentand highly debilitating flares, gouty arthritis, and significantlyreduced quality of life.

The increased morbidity and mortality of patients with chronic severe gout are associated withtophi, which are not effectively addressed by currently available treatments.

CLINICAL CONSEQUENCES & UNMET NEED

SEL-212

Selecta’s SEL-212 is an investigational

medicine in Phase 2 clinical development

designed to address the acute symptoms of

chronic severe gout by significantly lowering

serum uric acid to levels conducive to the

resolution of tophi while avoiding adverse

reactions due to immunogenicity.

160,000 Of the 8 million people in the U.S. with gout, 160,000 suffer from chronic severe gout and are seen by rheumatologists

23%

glasspiercing skin

severeburn

breaking a bone

34% 28%

~25 lost workdays per year

• Recurrent and debilitating flares that can last 7-14 days

• Gouty arthritis

• Significantly reduced quality of life

How chronic severe gout patients describe flare pain:

Lost productivity (patients under the age of 65):

ACUTESYMPTOMS1,2,3

1 https://www.hopkinsarthritis.org/arthritis-info/gout/clinical-presentation-of-gout/2 Men’s Health Network and Takeda Pharmaceuticals North America, 2010 Gout Attitudes Patient Survey.3 Edwards, Sundy, Forsythe, et al. Work Productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1):10-5.4 Black, Glazebrook, Bongartz, et.al. Dual-Energy Computed Tomography for the Evaluation of Gout and Calcium Crystal Deposits, 2010, Mayo Foundation for Medical Education and

Research.5 Patients with serum uric acid levels >10 mg/dL. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J

Med. 2012 Jul;125(7):679-687.6 Vincent, Gamble, House, et.al., Predictors of Mortality in People with Recent-onset Gout: A Prospective Observational Study, J Rheumatol 2017;44;368-373.

SEL-212

Designed to:

✓ Significantly lower serum uric acid to levels conducive to rapid tophi dissolution

✓ Avoid immunogenicity normally associated with uricase enzyme therapy, which can comprise its safety and effectiveness

✓ Reduce incidence of gout flares following treatment initiation

visible tophi

gout

inflamed joint

swelling

uric acid crystals

tophi

Survival rate of gout patientsat year 8

hidden uric acid deposits4

No tophus Tophi present

85%

52%

2.9x higher mortality risks

86% have chronic kidney disease stage ≥2

66% have hypertension

65% are obese

33% have had heart failure

33% have diabetes

23% have myocardial infarction

12% have had a stroke